Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

Macrophages in human cancer: Current and future aspects

 

Michael R Mallmann†§, Susanne V Schmidt§, Joachim L Schultze§

Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
§ Genomics and Immunoregulation, LIMES-Institute, University of Bonn, Carl-Troll-Str. 53, D-53115 Bonn, Germany

Address correspondence and reprint requests to Prof. Dr. Joachim L. Schultze,
Genomics and Immunoregulation, LIMES-Institute, University of Bonn,
Carl-Troll-Str. 31, D-53115 Bonn, Germany
E-Mail address: j.schultze@uni-bonn.de

 

May 2012

 

 

Introduction

As cancer represents a very diverse biology depending on the genetic background, the organ of origin and confounding factors it remains ambitious to dissect this complex cellular microenvironment into its main driving factors. Among these factors an important role has been attributed to both the adaptive and innate immunity. For a long time, the immune regulatory capacity (e.g. regulatory T cells) of the adaptive immune system was a major focus of research concerning the involvement of immune cells in the tumor microenvironment with only few reports published on its role in tumor growth promotion and metastasis.
In contrast terms such as angiogenesis, tumor growth or metastasis have been attributed to cells of innate immune origin (Hicks et al., 2006). The innate immune system is represented by different cell subsets including natural killer (NK) cells, dendritic cells (DC), neutrophils, and macrophages (MΦ). Tumor-associated macrophages (TAMs) constitute a major part of the leukocytic infiltrate in human cancer and the amount of tumor infiltrating macrophages has early been associated with clinical outcome (Mantovani et al., 2008; Pollard, 2009). When assessing studies that identified TAMs simply as CD68+ cells it is challenging to assign a strict pro- or anti-tumorous function to the TAM infiltrate. Nevertheless, macrophage infiltration is associated with poor prognosis in breast cancer (Finak et al., 2008; Beck et al., 2009), Hodgkin's lymphoma (Steidl et al., 2010), T-cell lymphoma (Niino et al., 2010), cervical cancer (Steidl et al., 2010; Lenz et al., 2008; Hammes et al., 2007; Zhang et al., 2011c; Kamper et al., 2011) and uveal melanoma (Bronkhorst et al., 2011). In contrast, it has been linked with a favorable prognosis in colorectal and gastric cancer (Forssell et al., 2007; Sconocchia et al., 2011; Ohno et al., 2003). Interestingly, several studies now confirm that the location of TAMs in the tumor microenvironment and in regard to tumor cells seems to influence their prognostic role (Ohno et al., 2003; Allavena and Mantovani, 2012). In colon cancer for example, higher macrophage infiltration at the invasive front of the tumor is associated with both an improvement of overall survival and reduced hepatic metastasis (Zhou et al., 2010).
The classical six hallmarks of cancer are cell growth, ignoring growth-inhibition, the avoidance of cell death, replication without limitation, sustained angiogenesis and invasion through basement membranes into circulation (Hanahan and Weinberg, 2000). Growing knowledge on the biology of cancer stresses the role of the immune system, in particular macrophages, on several aspects of tumor biology. It more and more becomes clear that beside the classical six hallmarks, novel hallmarks of cancer can be assigned to cells of the microenvironment. Tumor-associated macrophages as part of the tumor microenvironment are involved in novel hallmarks of cancer such as tumor-promoting inflammation and avoidance of immune destruction. Moreover, they are actively involved in all classical six hallmarks by exerting TAM-specific tumor-sustaining properties discussed below (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011) .

 

Origin and activation status of macrophages

Macrophages are in general believed to arise from circulating monocytes that emigrate from blood vessels and differentiate into macrophages in the peripheral tissue. A variety of tissue associated macrophages exist that exert an important role in tissue homeostasis. Under homeostatic conditions, tissue macrophages comprise langerhans cells in the epidermis, osteoclast's in the bone, alveolar macrophages in the lung, red-pulp, white-pulp, marginal-zone and metallophilic macrophages in the spleen, kupffer cells in the liver and microglial cells in the central nervous system (Gordon and Taylor, 2005). In general tissue macrophages are believed to exhibit an intrinsic anti-inflammatory phenotype under homeostatic conditions (Murray and Wynn, 2011).
Macrophages are subject to a variety of concurrent stimuli in vivo. In vitro, macrophages can be polarized by single agent stimulation into rather pro- or anti-inflammatory macrophages. According to the stimulus, macrophages are divided into a simplified M1-like and M2-like phenotype classification analogue to the Th1-Th2 dichotomy in T cell biology (Biswas and Mantovani, 2010). The pro-inflammatory "classically activated" M1-like phenotype can be induced by inflammatory signals such as interferon, LPS and other bacterial stimuli and mediates defense against bacteria, protozoa and viruses (Murray and Wynn, 2011). The "alternatively activated" M2-like phenotype is induced by IL4 or IL-13 ("M2a"), LPS or immune complexes ("M2b"), IL-10 ("M2c") and is associated with wound healing and tissue repair (Gordon, 2003; Gordon and Martinez, 2010). As there exist more stimuli than those mentioned, consecutively a plethora of other macrophage phenotypes have been described both in vivo and in vitro. Whereas they often share some features with M1-like or M2-like macrophages they mostly exhibit their own unique set of immune-modulatory capabilities.

 

Current concepts of tumor associated macrophages

Macrophages play a prominent role in the stromal and leukocyte compartment in malignancy and distinct macrophage subsets in cancer have been described (Mantovani et al., 2008; Pollard, 2009; Grivennikov et al., 2010; Mantovani et al., 2010a). As macrophages in human cancer can neither be classified into classical activated M1-like or alternatively activated M2-like macrophages they are termed tumor-associated macrophages (TAMs). Macrophages represent a cell type with an extreme functional plasticity enabling them to integrate and respond to different stimuli (Stout et al., 2009). Despite profound functional differences between human and murine macrophages, most functional properties of TAM subtypes have been studied in murine cancer models due to the difficulty to molecularly characterize small numbers of macrophages from human tumor specimens (Clark et al., 2007).

Mechanisms of macrophage recruitment and macrophage polarization

Macrophages are among the first immune cells to infiltrate already preinvasive tumorous lesions and persist during the development into invasive cancer (Clark et al., 2007). Cancer is associated with inflammation that results in recruitment of bone marrow derived cells (Hanahan and Weinberg, 2011; Coussens and Werb, 2002). Growth factors like CSF-1 (colony stimulating factor 1) and vascular epithelial growth factor (VEGF), but also monocyte chemotactic protein-1 (MCP-1) as well as several CCL chemokines and other molecules have been shown to induce chemotaxis of monocytes into the tumor environment (Lewis and Pollard, 2006). In an elegant study in three different murine tumor models (the BALB/c 4T1 mammary tumor model, the BALB/c mammary adenocarcinoma TS/A model and the C57BL/6 3LL lung carcinoma model) the inflammatory Ly6Chi monocyte subset was shown to be the major monocyte subset to localize into the tumor and to give rise to TAM subsets in the tumor (Movahedi et al., 2010). With respect to the specific tumor, the molecules are secreted by tumor cells themselves or adjacent stromal cells. In skin carcinogenesis for example carcinogen application induces proliferation of fibroblasts that secrete MCP-1 which results in chemotaxis of macrophages. Neutralization of MCP-1 almost completely blocks this accumulation of macrophages in the tumor (Zhang et al., 2011a). VEGF, beside its strong angiogenic role, recruits monocytes into the tumor microenvironment and blockade of VEGF by bevacizumab results not only in reduced vessel density, but also in reduced TAM infiltration (Roland et al., 2009).
Once migrated to the tumor site monocytes differentiate into macrophages under the influence of macrophage colony-stimulating factor (M-CSF). Further tumor cell-derived factors drive macrophage polarization into one of the TAM subpopulations described below. In general the induction of a TAM related phenotype has been brought in context with tumor cell derived mediators such as M-CSF (Duluc et al., 2007), IL-4, IL-10, IL-6 (Duluc et al., 2007; Song et al., 2009), transforming growth factor β (TGF-β1), prostaglandin E2 (PGE2) (Lewis and Pollard, 2006; Heusinkveld et al., 2011), hyaluron fragments (Kuang et al., 2007) and the leukemia inhibitory factor (LIF) (Duluc et al., 2007). In cervical cancer, monocytes are skewed from a DC towards a macrophage phenotype by the production of PGE2 and IL-6 from tumor cells (Heusinkveld et al., 2011; Kim et al., 2011).
As stated above, the terms "classically activated" and "alternatively activated wound healing" are counterintuitive in the description of tumor-associated macrophages as the conditions that dominate the tumor microenvironment are rarely the same as in infection (exceptions might be true for infectious related cancers such as cervical cancer and vulvar cancer). Despite this statement researchers attempt to classify tumor-associated macrophages into the M1-like/M2-like terminology as of similarities in expressed marker profiles. It is yet unclear whether similarities between certain tumor-associated macrophages and the M1-like or M2-like macrophages are due to the different types of tumors that were investigated, as proposed by some researchers, or whether there might be a "M1-like/M2-like switch" during tumor progression. Despite the vast majority of reports describing TAM phenotypes that share properties with M2 macrophages, TAM with expression of both M2-like and M1-like markers have been described as well (Biswas et al., 2006). These TAMs show high expression of genes encoding immunosuppressive cytokines (Il10, Tgfb1), phagocytosis-related receptors/molecules (Msr2, C1q) and inflammatory chemokines (Ccl2, Ccl5) as well as IFN-inducible chemokines (Cxcl9, Cxcl10, Cxcl16) (Biswas et al., 2006). Others have shown mixed M1-like (CD14+HLA-DR+) and M2-like (CD14+CD163+) TAM infiltration (Buddingh et al., 2011). These TAMs are sarcoma associated, but similar results exist for carcinoma as well (Movahedi et al., 2010). Conversely TAMs in cutaneous squamous cell carcinoma partially express the M2-like markers CD209 and CCL18, others express M1-like markers STAT1, IL-23, IL-12 and CD127 and again others express markers of both M1-like and M2-like macrophages (Pettersen et al., 2011). In other carcinomas there are TAMs with a predominantly M2-like marker expression status (Ma et al., 2010). Typical genes that are expressed by TAMs include IL-1, IL-6 and tumor necrosis factor α (TNF-α) (Lewis and Pollard, 2006). In consequence, TAMs are often termed M2-like macrophages by many researches despite their integration of probably much more diverse stimuli than only IL-4 and/or M-CSF which suggests that a much more dynamic model of macrophage activation in tumor immunology must be found to usefully characterize TAMs (Pettersen et al., 2011). Independent from the assignment to the M1-like or M2-like macrophage class, the underlining intracellular pathways that are activated in TAM are far from understood. Several pathways have been shown to be important for specific functions of TAMs, for example an Ets2-driven transcriptional program as well as a Wnt-signaling program have been associated with invasion and metastasis in murine breast cancer associated TAMs (Zabuawala et al., 2010; Ojalvo et al., 2010) .
Consequently, additional TAM subpopulations will likely be identified with specialized tumor-associated properties that can be allocated functionally to cancer specific needs such as growth, invasion, angiogenesis and metastasis.

Pro-inflammatory and growth promoting properties of TAMs

Tumor-promoting inflammation and avoidance of immune destruction represent novel hallmarks of cancer (Hanahan and Weinberg, 2011). Macrophages have been shown to support tumor cell growth by the activation of different pathways. Several soluble growth factors, eg. IL-1, IL-6, TNF-α, TGF-β, epidermal growth factor (EGF), platelet-derived growth factor (PDGF) produced by macrophages have been indicated to be involved in tumor cell growth, (Lewis and Pollard, 2006). TNFα is produced by tumor cells and by inflammatory cells in chronic inflammation. It promotes cell survival by induction of anti-apoptotic molecules via TNFR1 and TNFR2 (Lin and Karin, 2007). EGF plays an important role in murine breast cancer (Joyce and Pollard, 2009). TAMs are major producers of EGF, and there exists interplay between EGF producing TAMs and EGFR expressing tumor cells, which reciprocally produce M-CSF to support macrophage survival and EGF production. Another important activating pathway in TAMs is mediated by signal transducer and activator of transcription 3 (STAT3) known to result in IL-6 expression. This pro-inflammatory cytokine is known to induce proliferation of malignant cells (Lin and Karin, 2007; Grivennikov et al., 2009; Bromberg and Wang, 2009) and IL-6 has been found to have a pivotal role in Kaposi sarcoma, multiple myeloma, Hodgkin lymphoma, breast cancer, ovarian cancer and others (Osborne et al., 1999; Bommert et al., 2006; Cozen et al., 2004; Berger, 2004; Stone et al., 2012). Opposing roles have been attributed to TGF-β. Whereas TGF-β might inhibit tumor growth by reducing IL-6 secretion (Lin and Karin, 2007; Derynck et al., 2001), enhanced TGF-β secretion is often observed in carcinoma and is associated with enhanced epithelial-mesenchymal transition (EMT). EMT results in higher invasiveness of epithelial tumor cells and metastasis due to changed expression levels of adhesion molecules and metalloproteinases (Derynck et al., 2001). TGF-β production by tumor cells also induces IRAK-M (Interleukin-1 receptor-associated kinase) a negative regulator of Toll-like receptor signaling in TAM, which is part of the immunosuppressive phenotype of TAM (Standiford et al., 2011).

Immunosuppressive properties of TAMs

Immunosuppressive functions of TAMs seem to be contradictory to the strong inflammatory tumor-microenvironment and the inflammatory properties of macrophages. Although TAMs produce several chemokines that are associated with inflammation in immunity against pathogens, under sterile inflammatory conditions in cancer these molecules rather exert a growth promoting influence on tumor cells. TAMs are poor producers of IL-12 but produce IL-10 and TGFβ (Sica et al., 2000). This effect might be due to STAT3 activation in TAMs opposing STAT1 driven Th-1 anti-tumor responses (Allavena and Mantovani, 2012; Yu et al., 2009). Expression of MHC class II molecules on TAMs is actively downregulated by tumor cell derived TGF-β1, IL-10 and PGE2 (Lewis and Pollard, 2006).
Direct inhibition of immune responses by TAMs has been described as well (Kryczek et al., 2006). IL-10 and TNF-α in the tumor milieu induce expression of PD-L1 (also termed B7-H1) on the membrane of tumor-associated macrophages. Although naïve T cells can be stimulated via PD-L1, its most prominent role is the inhibition of activated effector T cells through the PD-1 receptor (Kuang et al., 2009).
Allavena and Mantovani reported an additional - indirect - mechanism of creating an anti-inflammatory tumor milieu, namely the recruitment of other non-inflammatory immune cells into the tumor microenvironment (Allavena and Mantovani, 2012). In this context, CCL17 and CCL22 produced by TAMs have been implicated to predominantly attract Th2 and Tregs that are non-cytotoxic cells (Allavena and Mantovani, 2012; Mantovani et al., 2010b). Macrophage-derived CCL18 recruits rather naïve T cells that are primed under immune regulatory conditions (Schutyser et al., 2002). In a murine model of colorectal cancer, F4/80+ TAMs were found to secrete large amounts of CCL20 attracting CCR6+ Treg cells to the tumor side (Liu et al., 2011).

Invasion and metastasis promoting properties of TAMs

Several macrophage-associated mechanisms in the tumor microenvironment exist that support invasion and metastasis of tumor cells. An invariant property of tissue macrophages is the production of matrix metalloproteinases, cathepsins and other proteolytic enzymes that degrade the extracellular matrix (Vasiljeva et al., 2006; Hagemann et al., 2004). While useful in wound healing this macrophage function subsequently allows tumor cells to invade and spread locally. Invasion is a prerequisite for metastasis as one of the major hallmarks of malignancy. As shown in the PyMT mouse tumor model, the property of tumor cells to invade tissues is dependent on macrophages (Goswami et al., 2005; Wyckoff et al., 2004). By producing CSF-1 and TNF-α, tumor cells recruit macrophages which produce metalloproteinases 2, 3, 7, and 9. Invasion of tumor cells is prominently accompanied by coordinated migration of macrophages (Goswami et al., 2005; Wyckoff et al., 2004). Intravital imaging has provided direct evidence that perivascular macrophages in mammary tumors are involved in the intravasation of cancer cells (Wyckoff et al., 2007). Moreover, either inhibition of EGF signaling or deletion of macrophages can reduce the number of tumor cells that enter the blood stream (Lewis and Pollard, 2006). Further molecular investigations revealed that especially invasive TAMs are a unique subpopulation of TAMs exhibiting increased WNT signaling and promoting carcinoma cell motility (Ojalvo et al., 2010).
Whereas the CSF-1/EGF signaling axis seems to promote invasiveness in certain cancer models, in others an important role in invasiveness has been attributed to EMT (Thiery, 2002). Expression of mesenchymal markers is correlated with TAM infiltration in a F9-teratocarcinoma model and depletion of macrophages results in a decrease of mesenchymal associated genes (Bonde et al., 2012). Moreover, growth of tumor cells in macrophage-conditioned media results in EMT and enhanced invasiveness. EMT can be induced in cancer cells in vitro by addition of TGF-β to the cell culture and experimental data suggest that TGF-β is also the driving force of macrophage-induced EMT in vivo (Derynck et al., 2001; Bonde et al., 2012).

Lymphangiogenesis promoting properties of TAMs

Depending on the tumor characteristics tumors show either a lymphatic or a haematogenic metastasis pattern. Degree of lymphangiogenesis predicts poor clinical prognosis in most malignant diseases. Tumor cells themselves show considerable production of lymphangiopoietic vascular endothelial growth factors (VEGF)-C and -D. In addition, macrophages can produce high amounts of VEGF-C and VEGF-D and macrophage infiltration is associated with peritumoral lymphangiogenesis in lung adenocarcinoma and cervical cancer (Zhang et al., 2011b; Utrera-Barillas et al., 2010). Schoppmann et al. identified a subset of VEGFR-3+ tumor-associated macrophages that stains for VEGF-C- and VEGF-D in human cancer probably being the main producers of these lymphangiopoietic factors (Schoppmann et al., 2002; Schoppmann et al., 2006). In SCC, VEGF-C expression is associated with CD68+ CD163+ TAMs, whereas other immune cells infiltrating the tumor such as CD3+ T cells or CD11c+ DC do not express this lymphangiogenesis marker (Moussai et al., 2011). In line with this, inhibition of VEGFR-3 signaling suppresses lymphangiogenesis in cancer and metastasis to regional lymph nodes (He et al., 2002). Moreover in mice models of inflammation-induced lymphangiogenesis, macrophages were found to form lymphatic-like tubes in vitro. Moreover they showed the ability to assemble into lymphatic vessels that arose de novo and expressed classical lymphatic endothelial markers such as LYVE-1, VEGFR-3, podoplanin and Prox-1 (Maruyama et al., 2005).

Angiogenesis promoting properties of TAMs

Cancer requires angiogenesis beyond a tumor size of a few millimeters. Hypoxic conditions in immunity against pathogens are frequent and macrophages have adapted to this condition by a specific genetic program under the control of the transcription factor family hypoxia-inducible factor HIF (Leek et al., 2002). Cancer angiogenesis is not dependent on one mechanism, but several pathways have been described. The neoangiogenesis in cancer development is known as "angiogenic switch". In general cancer cells have been shown to induce this angiogenic switch by production of angiogenic factors the most prominent being VEGF. Nevertheless angiogenesis is positively correlated with macrophage infiltration in various studies suggesting a possible role for this cell subset in angiogenesis (Rogers and Holen, 2011; Murdoch et al., 2008; Clear et al., 2010). In macrophages HIF-1 is induced under hypoxic conditions in the tumor microenvironment resulting in the production of pro-angiogenic molecules. Several macrophage derived molecules that are directly angiogenic (among those are VEGF, TNF-α, IL-8, CXCL8 and bFGF) and others that modulate angiogenesis (e.g. MMP2, MMP-7, MMP-9, MMP-12, COX-2) have been described (Lewis and Pollard, 2006). The most well-known element is VEGF that is produced by a specialized subset of TAMs in hypoxic areas of breast cancer (Lewis and Pollard, 2006). In murine tumor models these VEGF-producing cells can be identified by Tie-2 expression (De Palma et al., 2005). Mechanisms of modulation of angiogenesis other than VEGF comprise the Wnt-pathway dependent production of Flt1, an inhibitor of angiogenesis, in myeloid cells (Stefater et al., 2011), neurotrophin 5, FGF13, PDGFRα and Bv8 (Shojaei et al., 2007a; Shojaei et al., 2007b, Dong et al., 2004). Experimental mouse models using clodrolip depletion of TAMs have shown that macrophage depletion results in drastic reduction of vessel density and decrease in tumor growth (Zeisberger et al., 2006).

 

Figure 1: Induction of TAMs in the tumor microenvironment. Circulating monocytes are recruited into the tumor by growth factors and chemokines. Local presence of M-CSF causes the differentiation of monocytes to macrophages. Soluble tumor derived factors initiate the polarization of macrophages into TAMs leading to the expression of molecules that support angiogenesis, tumor growth and metastasis. Conversely TAMs secrete factors that induce local immune suppression by recruitment of Treg cells or suppress T cell responses directly.

 

Future concepts of tumor associated macrophages (TAM)

The Role of TAMs in Chemotherapy Resistance

Most of the functions that are attributed to TAMs are pro-tumoral, e.g. tumor progression, vascularization, invasion and metastasis. Cell death of cancer cells upon exposure to chemotherapy can occur in an immunogenic or a non-immunogenic way, in the past thought to be represented by necrosis and apoptosis, respectively (Zitvogel et al., 2008). New data suggest that this dichotomy is an oversimplification as necrosis can induce local immunosuppression as well as certain types of apoptosis are immunogenic which has been shown to be related to translocation of calreticulin to the cell surface (Vakkila and Lotze, 2004; Casares et al., 2005; Obeid et al., 2007). Immunogenic tumor cell death is thought to be a prerequisite for a contribution of the immune system to the eradication of cancer cells, called "bystander effect" (Zitvogel et al., 2006; Lake and van der Most, 2006). In the past, this effect has mainly been attributed to dendritic cells and T cells (Zitvogel et al., 2008; Storkus and Falo, 2007). In contrast, recent evidence suggests that macrophages are involved in the resistance of malignant tumors against chemotherapy. Cancer cells that are exposed to certain chemotherapy regimen secrete macrophage chemoattractant protein-1 (MCP-1) that results in the recruitment of MSF1 receptor expressing monocytes and macrophages into the tumor (Geller et al., 2010; Denardo et al., 2011). Blockade of macrophage infiltration by blockade of CSF1 receptor results in a partial depletion of TAMs with consecutive decrease of tumor progression, lung metastasis and vessel density in a murine model of breast cancer (Denardo et al., 2011). The emerging role of macrophages in chemotherapy resistance follows reports on the role of other leukocyte subsets for chemotherapy responses (Zitvogel et al., 2008). These first results identify a chemoprotective TAM subset and raise the possibility of targeting or reprogramming these chemoprotective TAMs to improve efficiency of standard anticancer treatments (De Palma and Lewis, 2011).

Re-Polarization of TAMs

The plastic nature of macrophages allows to re-polarize them into a more tumoricidal phenotype than the tumor associated phenotype, for example the pro-inflammatory M1-like phenotype. Reversion of the tumor-associated M2-like status into a M1-like phenotype has been shown to improve anti-tumor responses. Especially IFNg, nitric oxide and IL-12 produced by macrophages or expressed exogenously repress tumor cell growth (Lewis and Pollard, 2006; Peron et al., 2004). In general, this can be accomplished by different methods. A combination of chemotherapy with vincristine, cyclophosphamide and doxorubicin together with immunotherapy with CpG-ODN led to a shift in the TAM population from a rather M2-like towards a M1-like phenotype with upregulation of MHC II, IFN-γ, TNF-α and IL-12 (Buhtoiarov et al., 2011). Zoledronic acid, besides its macrophage depleting effect, has been shown to reduce VEGF expression in TAMs as well as to induce expression of iNOS, one of the hallmark genes of M1-like polarization (Coscia et al., 2010). The histidine-rich glycoprotein (HRG) skews TAM polarization away from the M2-like to a M1-like phenotype and suppresses placental like growth factor (PLGF) (Rolny et al., 2011; Huang et al., 2011). Inhibition of PGE2 production in tumor cells by COX inhibitors and blocking of IL-6 can prevent differentiation of monocytes into M2-like macrophages in the tumor microenvironment (Heusinkveld et al., 2011). Interaction of already polarized M2-like macrophages with Th1 cells results in a repolarization of M2-like into M1-like macrophages with induction of costimulatory molecules and production of IL-12. Similar effects could be observed by stimulating M2-like cells with CD40L+ cells and IFN-γ (Heusinkveld et al., 2011).

Therapeutic depletion of TAMs

TAM infiltration in tumors is associated with bad prognosis and besides repolarization of macrophages, therapeutic depletion might be an attractive approach against invasion, angiogenesis, tumor growth and metastasis as well. For depletion of macrophages, clodronate-encapsulated liposomes are most often used in the experimental murine setting. Depletion of TAMs by this method in mouse models has been shown to significantly inhibit tumor growth (Zeisberger et al., 2006).
Moreover, recent studies suggest that medications with proven clinical benefit exert part of their action through inhibition or depletion of macrophages. Bisphosphonates are mainly used to treat osteoporosis and have been shown to lower the incidence of bone metastases in multiple myeloma, breast and prostate cancer (Rogers and Holen, 2011). Bisphosphonates mainly affect osteoclasts, but macrophages that arise from the same precursors are affected as well. In macrophages bisphosphonates induce apoptosis in vitro and inhibit M-CSF induced proliferation (Rogers and Holen, 2011). Moreover, in murine models, the bisphosphonate zoledronic acid decreased macrophage infiltration into the tumor, VEGF expression and macrophage associated MMP-9 expression (Giraudo et al., 2004; Tsagozis et al., 2008).
Depletion of macrophages was shown to decrease tumor growth in various murine cancer models: in murine lung cancer, depletion of macrophages results in a reduction of macrophage infiltration with reduction of bone metastasis; in murine breast cancer, macrophage infiltration and neo-vascularization is impaired and a shift from M2-like to M1-like phenotype is observed; in teratocarcinoma and rhabdomyosarcoma, depletion of macrophages results in reduction of tumor volume and reduction of blood vessel density, respectively (Rogers and Holen, 2011). Moreover, depletion of macrophages has been shown to increase response to chemotherapy, for example sorafenib in a murine model of metastatic liver cancer. In this model, sorafenib induced macrophage recruitment is inhibited by concomitant application of zoledronic acid and results in decreased tumor angiogenesis and lung metastasis (Zhang et al., 2010).

Consequently, the development of effective strategies against cancer might target not only the cancer cell, but also other players in the tumor microenvironment, among which the tumor-associated macrophage plays a prominent role.

Bibliography

KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways.
Osborne J, Moore PS, Chang Y.
Hum Immunol. 1999 Oct;60(10):921-7.
PMID 10566591
 
The hallmarks of cancer.
Hanahan D, Weinberg RA.
Cell. 2000 Jan 7;100(1):57-70. (REVIEW)
PMID 10647931
 
Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages.
Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A.
J Immunol. 2000 Jan 15;164(2):762-7.
PMID 10623821
 
TGF-beta signaling in tumor suppression and cancer progression.
Derynck R, Akhurst RJ, Balmain A.
Nat Genet. 2001 Oct;29(2):117-29. (REVIEW)
PMID 11586292
 
Inflammation and cancer.
Coussens LM, Werb Z.
Nature. 2002 Dec 19-26;420(6917):860-7. (REVIEW)
PMID 12490959
 
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.
J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.
PMID 12048269
 
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL.
Cancer Res. 2002 Mar 1;62(5):1326-9.
PMID 11888900
 
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.
Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D.
Am J Pathol. 2002 Sep;161(3):947-56.
PMID 12213723
 
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma.
Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J.
J Biol Chem. 2002 Jul 5;277(27):24584-93. Epub 2002 Apr 26.
PMID 11978786
 
Epithelial-mesenchymal transitions in tumour progression.
Thiery JP.
Nat Rev Cancer. 2002 Jun;2(6):442-54. (REVIEW)
PMID 12189386
 
Alternative activation of macrophages.
Gordon S.
Nat Rev Immunol. 2003 Jan;3(1):23-35. (REVIEW)
PMID 12511873
 
The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients.
Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N.
Anticancer Res. 2003 Nov-Dec;23(6D):5015-22.
PMID 14981961
 
The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality.
Berger FG.
Breast Cancer Res Treat. 2004 Dec;88(3):281-5. (REVIEW)
PMID 15609131
 
IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma.
Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM.
Blood. 2004 Apr 15;103(8):3216-21. Epub 2003 Dec 30.
PMID 15070705
 
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.
Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N.
EMBO J. 2004 Jul 21;23(14):2800-10. Epub 2004 Jul 1.
PMID 15229650
 
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
Giraudo E, Inoue M, Hanahan D.
J Clin Invest. 2004 Sep;114(5):623-33.
PMID 15343380
 
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.
Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C.
Carcinogenesis. 2004 Aug;25(8):1543-9. Epub 2004 Mar 25.
PMID 15044327
 
Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12.
Peron JM, Couderc B, Rochaix P, Douin-Echinard V, Asnacios A, Souque A, Voigt JJ, Buscail L, Vinel JP, Favre G.
J Gastroenterol Hepatol. 2004 Apr;19(4):388-96.
PMID 15012775
 
Inflammation and necrosis promote tumour growth.
Vakkila J, Lotze MT.
Nat Rev Immunol. 2004 Aug;4(8):641-8.
PMID 15286730
 
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J.
Cancer Res. 2004 Oct 1;64(19):7022-9.
PMID 15466195
 
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G.
J Exp Med. 2005 Dec 19;202(12):1691-701.
PMID 16365148
 
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L.
Cancer Cell. 2005 Sep;8(3):211-26.
PMID 16169466
 
Monocyte and macrophage heterogeneity.
Gordon S, Taylor PR.
Nat Rev Immunol. 2005 Dec;5(12):953-64. (REVIEW)
PMID 16322748
 
Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.
Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE, Condeelis JS.
Cancer Res. 2005 Jun 15;65(12):5278-83.
PMID 15958574
 
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages.
Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW.
J Clin Invest. 2005 Sep;115(9):2363-72.
PMID 16138190
 
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).
Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A.
Blood. 2006 Mar 1;107(5):2112-22. Epub 2005 Nov 3.
PMID 16269622
 
Signalling and survival pathways in multiple myeloma.
Bommert K, Bargou RC, Stuhmer T.
Eur J Cancer. 2006 Jul;42(11):1574-80. Epub 2006 Jun 22. (REVIEW)
PMID 16797970
 
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.
Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z.
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7753-8. Epub 2006 May 8.
PMID 16682640
 
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W.
J Exp Med. 2006 Apr 17;203(4):871-81. Epub 2006 Apr 10.
PMID 16606666
 
A better way for a cancer cell to die.
Lake RA, van der Most RG.
N Engl J Med. 2006 Jun 8;354(23):2503-4.
PMID 16760453
 
Distinct role of macrophages in different tumor microenvironments.
Lewis CE, Pollard JW.
Cancer Res. 2006 Jan 15;66(2):605-12. (REVIEW)
PMID 16423985
 
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival.
Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P.
Surgery. 2006 Jun;139(6):839-46.
PMID 16782443
 
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C, Reinheckel T.
Cancer Res. 2006 May 15;66(10):5242-50.
PMID 16707449
 
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA.
Br J Cancer. 2006 Aug 7;95(3):272-81. Epub 2006 Jul 11.
PMID 16832418
 
Cancer despite immunosurveillance: immunoselection and immunosubversion.
Zitvogel L, Tesniere A, Kroemer G.
Nat Rev Immunol. 2006 Oct;6(10):715-27. Epub 2006 Sep 15.
PMID 16977338
 
Dynamics of the immune reaction to pancreatic cancer from inception to invasion.
Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH.
Cancer Res. 2007 Oct 1;67(19):9518-27.
PMID 17909062
 
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.
Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M, Jeannin P.
Blood. 2007 Dec 15;110(13):4319-30. Epub 2007 Sep 11.
PMID 17848619
 
High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.
Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R.
Clin Cancer Res. 2007 Mar 1;13(5):1472-9.
PMID 17332291
 
Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation.
Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS.
Gynecol Oncol. 2007 Apr;105(1):157-65. Epub 2007 Jan 16.
PMID 17229459
 
Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes.
Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L.
Blood. 2007 Jul 15;110(2):587-95. Epub 2007 Mar 29.
PMID 17395778
 
A cytokine-mediated link between innate immunity, inflammation, and cancer.
Lin WW, Karin M.
J Clin Invest. 2007 May;117(5):1175-83. (REVIEW)
PMID 17476347
 
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G.
Nat Med. 2007 Jan;13(1):54-61. Epub 2006 Dec 24.
PMID 17187072
 
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N.
Nat Biotechnol. 2007a Aug;25(8):911-20. Epub 2007 Jul 29.
PMID 17664940
 
Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N.
Nature. 2007b Dec 6;450(7171):825-31.
PMID 18064003
 
A 'good death' for tumor immunology.
Storkus WJ, Falo LD Jr.
Nat Med. 2007 Jan;13(1):28-30.
PMID 17206130
 
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.
Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J.
Cancer Res. 2007 Mar 15;67(6):2649-56.
PMID 17363585
 
Stromal gene expression predicts clinical outcome in breast cancer.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M.
Nat Med. 2008 May;14(5):518-27. Epub 2008 Apr 27.
PMID 18438415
 
Stromal gene signatures in large-B-cell lymphomas.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.
N Engl J Med. 2008 Nov 27;359(22):2313-23.
PMID 19038878
 
Cancer-related inflammation.
Mantovani A, Allavena P, Sica A, Balkwill F.
Nature. 2008 Jul 24;454(7203):436-44. (REVIEW)
PMID 18650914
 
The role of myeloid cells in the promotion of tumour angiogenesis.
Murdoch C, Muthana M, Coffelt SB, Lewis CE.
Nat Rev Cancer. 2008 Aug;8(8):618-31. Epub 2008 Jul 17. (REVIEW)
PMID 18633355
 
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
Tsagozis P, Eriksson F, Pisa P.
Cancer Immunol Immunother. 2008 Oct;57(10):1451-9. Epub 2008 Feb 23.
PMID 18297280
 
Immunological aspects of cancer chemotherapy.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.
Nat Rev Immunol. 2008 Jan;8(1):59-73. (REVIEW)
PMID 18097448
 
The macrophage colony-stimulating factor 1 response signature in breast carcinoma.
Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB.
Clin Cancer Res. 2009 Feb 1;15(3):778-87.
PMID 19188147
 
Inflammation and cancer: IL-6 and STAT3 complete the link.
Bromberg J, Wang TC.
Cancer Cell. 2009 Feb 3;15(2):79-80.
PMID 19185839
 
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M.
Cancer Cell. 2009 Feb 3;15(2):103-13.
PMID 19185845
 
Microenvironmental regulation of metastasis.
Joyce JA, Pollard JW.
Nat Rev Cancer. 2009 Apr;9(4):239-52. Epub 2008 Mar 12. (REVIEW)
PMID 19279573
 
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L.
J Exp Med. 2009 Jun 8;206(6):1327-37. Epub 2009 May 18.
PMID 19451266
 
Trophic macrophages in development and disease.
Pollard JW.
Nat Rev Immunol. 2009 Apr;9(4):259-70. (REVIEW)
PMID 19282852
 
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.
Mol Cancer Ther. 2009 Jul;8(7):1761-71. Epub 2009 Jun 30.
PMID 19567820
 
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS.
J Clin Invest. 2009 Jun;119(6):1524-36.
PMID 19411762
 
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages.
Stout RD, Watkins SK, Suttles J.
J Leukoc Biol. 2009 Nov;86(5):1105-9. Epub 2009 Jul 15. (REVIEW)
PMID 19605698
 
STATs in cancer inflammation and immunity: a leading role for STAT3.
Yu H, Pardoll D, Jove R.
Nat Rev Cancer. 2009 Nov;9(11):798-809. (REVIEW)
PMID 19851315
 
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
Biswas SK, Mantovani A.
Nat Immunol. 2010 Oct;11(10):889-96. Epub 2010 Sep 20. (REVIEW)
PMID 20856220
 
Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment.
Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA, Gribben JG.
Blood. 2010 Jun 17;115(24):5053-6. Epub 2010 Apr 7.
PMID 20375314
 
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.
Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M.
J Cell Mol Med. 2010 Dec;14(12):2803-15. doi: 10.1111/j.1582-4934.2009.00926.x.
PMID 19818098
 
Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer.
Geller MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S.
Int J Gynecol Cancer. 2010 Aug;20(6):918-25.
PMID 20683396
 
Alternative activation of macrophages: mechanism and functions.
Gordon S, Martinez FO.
Immunity. 2010 May 28;32(5):593-604. (REVIEW)
PMID 20510870
 
Immunity, inflammation, and cancer.
Grivennikov SI, Greten FR, Karin M.
Cell. 2010 Mar 19;140(6):883-99. (REVIEW)
PMID 20303878
 
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.
Ma J, Liu L, Che G, Yu N, Dai F, You Z.
BMC Cancer. 2010 Mar 25;10:112.
PMID 20338029
 
Molecular pathways and targets in cancer-related inflammation.
Mantovani A, Garlanda C, Allavena P.
Ann Med. 2010a Apr;42(3):161-70. (REVIEW)
PMID 20384432
 
The chemokine system in cancer biology and therapy.
Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R.
Cytokine Growth Factor Rev. 2010b Feb;21(1):27-39. Epub 2009 Dec 8. (REVIEW)
PMID 20004131
 
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA.
Cancer Res. 2010 Jul 15;70(14):5728-39. Epub 2010 Jun 22.
PMID 20570887
 
Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y, Takeya M, Ohshima K.
Pathol Int. 2010 Apr;60(4):278-83.
PMID 20403029
 
Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW.
J Immunol. 2010 Jan 15;184(2):702-12. Epub 2009 Dec 16.
PMID 20018620
 
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD.
N Engl J Med. 2010 Mar 11;362(10):875-85.
PMID 20220182
 
The role of macrophages and mast cells in lymphangiogenesis and angiogenesis in cervical carcinogenesis.
Utrera-Barillas D, Castro-Manrreza M, Castellanos E, Gutierrez-Rodriguez M, Arciniega-Ruiz de Esparza O, Garcia-Cebada J, Velazquez JR, Flores-Resendiz D, Hernandez-Hernandez D, Benitez-Bribiesca L.
Exp Mol Pathol. 2010 Oct;89(2):190-6. Epub 2010 Jun 25.
PMID 20599941
 
An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis.
Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, Rosol TJ, Fernandez S, Huang K, Leone G, Ostrowski MC.
Cancer Res. 2010 Feb 15;70(4):1323-33. Epub 2010 Feb 9.
PMID 20145133
 
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY.
Clin Cancer Res. 2010 Jul 1;16(13):3420-30. Epub 2010 Jun 22.
PMID 20570927
 
The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer.
Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ, Wan DS, Zeng YX, Zhang XS.
J Transl Med. 2010 Feb 8;8:13.
PMID 20141634
 
Detection of M2-macrophages in uveal melanoma and relation with survival.
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, Jager MJ.
Invest Ophthalmol Vis Sci. 2011 Feb 3;52(2):643-50. Print 2011 Feb.
PMID 20811059
 
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM.
Clin Cancer Res. 2011 Apr 15;17(8):2110-9. Epub 2011 Mar 3.
PMID 21372215
 
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL.
Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13.
PMID 21039467
 
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM.
Cancer Discov. 2011 Jun;1(1):54-67. Epub 2011 Jun 1.
PMID 22039576
 
Cancer: Macrophages limit chemotherapy.
De Palma M, Lewis CE.
Nature. 2011 Apr 21;472(7343):303-4.
PMID 21512566
 
Hallmarks of cancer: the next generation.
Hanahan D, Weinberg RA.
Cell. 2011 Mar 4;144(5):646-74. (REVIEW)
PMID 21376230
 
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.
Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH.
J Immunol. 2011 Aug 1;187(3):1157-65. Epub 2011 Jun 27.
PMID 21709158
 
Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity.
Huang Y, Snuderl M, Jain RK.
Cancer Cell. 2011 Jan 18;19(1):1-2.
PMID 21251607
 
Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.
Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F.
Haematologica. 2011 Feb;96(2):269-76. Epub 2010 Nov 11.
PMID 21071500
 
Consistent interactions between tumor cell IL-6 and macrophage TNF-? enhance the growth of human prostate cancer cells in the bone of nude mouse.
Kim SW, Kim JS, Papadopoulos J, Choi HJ, He J, Maya M, Langley RR, Fan D, Fidler IJ, Kim SJ.
Int Immunopharmacol. 2011 Jul;11(7):862-72. Epub 2011 Jan 18.
PMID 21251905
 
Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.
Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, Wang H, Chen J, Wang H.
PLoS One. 2011 Apr 29;6(4):e19495.
PMID 21559338
 
The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C.
Moussai D, Mitsui H, Pettersen JS, Pierson KC, Shah KR, Suarez-Farinas M, Cardinale IR, Bluth MJ, Krueger JG, Carucci JA.
J Invest Dermatol. 2011 Jan;131(1):229-36. Epub 2010 Sep 9.
PMID 20827282
 
Protective and pathogenic functions of macrophage subsets.
Murray PJ, Wynn TA.
Nat Rev Immunol. 2011 Oct 14;11(11):723-37. doi: 10.1038/nri3073. (REVIEW)
PMID 21997792
 
Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.
Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L, Belkin DA, Wang CQ, Bhuvanendran S, Johnson-Huang LM, Bluth MJ, Krueger JG, Lowes MA, Carucci JA.
J Invest Dermatol. 2011 Jun;131(6):1322-30. Epub 2011 Feb 10.
PMID 21307877
 
Tumour macrophages as potential targets of bisphosphonates.
Rogers TL, Holen I.
J Transl Med. 2011 Oct 17;9:177. (REVIEW)
PMID 22005011
 
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Akerud P, De Mol M, Salomaki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P.
Cancer Cell. 2011 Jan 18;19(1):31-44. Epub 2011 Jan 6.
PMID 21215706
 
Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.
Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC.
Int J Cancer. 2011 Jun 1;128(11):2663-72. doi: 10.1002/ijc.25609. Epub 2010 Oct 13.
PMID 20715106
 
TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth.
Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG.
Oncogene. 2011 May 26;30(21):2475-84. Epub 2011 Jan 31.
PMID 21278795
 
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells.
Stefater JA 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara N, Gerhardt H, Lang RA.
Nature. 2011 May 29;474(7352):511-5. doi: 10.1038/nature10085.
PMID 21623369
 
FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation.
Zhang J, Chen L, Xiao M, Wang C, Qin Z.
Am J Pathol. 2011a Jan;178(1):382-90. Epub 2010 Dec 23.
PMID 21224075
 
Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma.
Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF.
Med Oncol. 2011b Dec;28(4):1447-52. Epub 2010 Jul 30.
PMID 20676804
 
Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified.
Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y.
Leuk Lymphoma. 2011c Jan;52(1):46-52. Epub 2010 Nov 15.
PMID 21077742
 
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Allavena P, Mantovani A.
Clin Exp Immunol. 2012 Feb;167(2):195-205. doi: 10.1111/j.1365-2249.2011.04515.x. (REVIEW)
PMID 22235995
 
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors.
Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA.
BMC Cancer. 2012 Jan 24;12:35.
PMID 22273460
 
Paraneoplastic thrombocytosis in ovarian cancer.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.
N Engl J Med. 2012 Feb 16;366(7):610-8.
PMID 22335738
 
Written2012-05Michael R Mallmann, Susanne V Schmidt, Joachim L Schultze
of Obstetrics, Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany (MRM); Genomics, Immunoregulation, LIMES-Institute, University of Bonn, Carl-Troll-Str. 53, D-53115 Bonn, Germany (SVS, JLS)

Citation

This paper should be referenced as such :
Mallmann, MR ; Schmidt, SV ; Schultze, JL
Macrophages in human cancer: Current, future aspects
Atlas Genet Cytogenet Oncol Haematol. 2012;16(10):765-774.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Deep/MacrophagesInCancerID20112.htm

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:22:19 CEST 2017


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.